Menu
Log in

FDA Drug Safety Communication

September 26, 2017 2:57 PM | Anonymous

FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. This provides updated information to the FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning issued on August 31, 2016.

To learn more click here: https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm

Education

Non-members interested in CME must create a profile with AOAAM. Subscribe now or Join Us to receive the full benefits of membership.

Latest News  read more


The 8-hour MOUD Training

Hot Topics in

Addiction Medicine
Webinars 

On-demand CME

- Live CME



The mission of the American Osteopathic Academy of Addiction Medicine is to improve the health of individuals and families burdened with the disease of addiction.

Powered by Wild Apricot Membership Software